NASDAQ: AEMDAethlon Medical Inc Stock
$1.76-0.21 (-10.66%)
Updated Jun 13, 2025
AEMD Price
$1.76
Fair Value Price
$1.79
Market Cap
$3.18M
52 Week Low
$1.75
52 Week High
$8.44
P/E
-0.14x
P/B
0.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.51
Operating Cash Flow
-$9M
Beta
0.82
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AEMD Overview
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AEMD's potential to beat the market
- AEMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AEMD
RankedUnranked of 108
RankedUnranked of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important AEMD news, forecast changes, insider trades & much more!
AEMD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AEMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AEMD ($1.76) is undervalued by 1.75% relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AEMD ($1.76) is not significantly undervalued (1.75%) relative to our estimate of its Fair Value price of $1.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AEMD due diligence checks available for Premium users.
Valuation
AEMD fair value
Fair Value of AEMD stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$1.79
Undervalued by
1.75%
AEMD ($1.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AEMD ($1.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AEMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
35.6x
Market
31.36x
AEMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
3.99x
AEMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AEMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
AEMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.5M
Liabilities
$2.2M
Debt to equity
0.51
AEMD's short-term assets ($4.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEMD's short-term assets ($4.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AEMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$2.2k
Financing
-$7.1k
AEMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AEMD vs Medical Device Stocks
Aethlon Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.